# Performance and Safety of IRIDIUM GARZE in Blepharitis or Blepharconjunctivitis Adjuvant Treatment

> **NCT07431385** · NA · RECRUITING · sponsor: **Fidia Farmaceutici s.p.a.** · enrollment: 80 (estimated)

## Conditions studied

- Blepharitis
- Blepharoconjunctivitis

## Interventions

- **DEVICE:** IRIDIUM GARZE

## Key facts

- **NCT ID:** NCT07431385
- **Lead sponsor:** Fidia Farmaceutici s.p.a.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-17
- **Primary completion:** 2026-03
- **Final completion:** 2026-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431385, "Performance and Safety of IRIDIUM GARZE in Blepharitis or Blepharconjunctivitis Adjuvant Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07431385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*